The advent of therapeutic modalities, including intravitreally injected vascular endothelial growth factor (VEGF) inhibitors has resulted in a marked reduction in the prevalence rate of blindness in the past few years; however, the incidence of MSVI showed no significant decline [19,20]. This evidence concerns the gene VEGFA and blindness (disorder).